Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Fuji
US Army
Cipla
Fish and Richardson
Johnson and Johnson
Deloitte
Boehringer Ingelheim
Queensland Health
Dow

Generated: August 19, 2017

DrugPatentWatch Database Preview

Patiromer sorbitex calcium - Generic Drug Details

« Back to Dashboard

What are the generic sources for patiromer sorbitex calcium and what is the scope of patiromer sorbitex calcium patent protection?

Patiromer sorbitex calcium
is the generic ingredient in one branded drug marketed by Relypsa Inc and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Patiromer sorbitex calcium has one hundred and twenty-four patent family members in twenty-one countries.

One supplier is listed for this compound.

Summary for Generic Name: patiromer sorbitex calcium

Tradenames:1
Patents:10
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list1,773
Drug Prices:see low prices
DailyMed Link:patiromer sorbitex calcium at DailyMed

Pharmacology for Ingredient: patiromer sorbitex calcium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-003Oct 21, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-002Oct 21, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-001Oct 21, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-002Oct 21, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-003Oct 21, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: patiromer sorbitex calcium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,282,960Ion binding compositions► Subscribe
7,429,394Ion binding compositions► Subscribe
8,409,561Methods and compositions for treatment of ion imbalances► Subscribe
7,776,319Methods and compositions for treatment of ion imbalances► Subscribe
8,445,014Ion binding compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: patiromer sorbitex calcium

Country Document Number Estimated Expiration
European Patent Office2365988► Subscribe
United Kingdom0906966► Subscribe
European Patent Office2184059► Subscribe
Denmark2269589► Subscribe
South Korea20070007168► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
McKesson
Chinese Patent Office
Dow
Mallinckrodt
QuintilesIMS
Deloitte
Novartis
Medtronic
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot